Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye imaging study aims to predict who will lose sight from AMD

NCT ID NCT05698316

Knowledge-focused Sponsor: Association for Innovation and Biomedical Research on Light and Image Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study collected eye images from 1,000 people with intermediate age-related macular degeneration (AMD) to create a detailed database. Researchers will analyze these images to find signs that predict whether the disease will worsen to advanced stages. The goal is to improve early detection and monitoring, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which patients with intermediate AMD will develop vision loss, enabling earlier monitoring or treatment.
What could go wrong
This is an observational study that builds a database, not a treatment trial. It may not lead to immediate clinical changes, and the predictive models need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,000 people

The number who actually took part.

Started

May 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with Age-related macular degeneration (AMD)

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Each dataset per patient should have one eye as the study eye with: * Intermediate AMD with no atrophy and no subretinal drusenoid deposits * Intermediate AMD with no atrophy with subretinal drusenoid deposits * Intermediate AMD with early atrophy (iRORA) with no Subretinal drusenoid deposits * Intermediate AMD with early atrophy (iRORA) with Subretinal drusenoid deposits * Intermediate AMD with evidence of cRORA Non-study eye images will not be exported but information about the status of the macula should be added using the following options: * Established Geographic Atrophy (cRORA) * Exudative AMD (presence of MNV) * Early AMD * Healthy macula Exclusion Criteria: * Both eyes have exudative AMD or geographic atrophy at baseline. * Co-existent ocular disease: Any other ocular condition that, in the investigator's opinion, might affect or alter visual acuity during the study. * Any patient who has opted out of their information being used for research nationally or locally at any Member Site.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration Atrophy dry age related macular degeneration macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration Atrophy Intermediate AMD Prediction

Contacts and locations

Locations

  • AIBILI-CEC (AIBILI- Clinical Trials Centre)

    Coimbra, Portugal

  • Clinical Eye Research Centre - St. Paul's Eye Unit, Royal Liverpool University Hospital

    Liverpool, United Kingdom

  • Clinical Trial Unit, Dep. Ophth., Gloucestershire Hospitals NHS Foundation Trust

    Cheltenham, United Kingdom

  • Clínica Oftalmológica AIKEN / Fundación Aiken de la Comunitat Valenciana

    Valencia, Spain

  • Department of Ophthalmology Justus/Liebig/University/Giessen

    Giesen, Germany

  • Department of Ophthalmology Porto Medical School / Hospital S. João

    Porto, Portugal

  • Department of Ophthalmology Radboud University Medical Centre Nijmegen

    Nijmegen, Netherlands

  • Department of Ophthalmology St. Franziskus/Hospital Münster

    Münster, Germany

  • Department of Ophthalmology University of Bonn

    Bonn, Germany

  • Department of Ophthalmology University of Freiburg

    Freiburg im Breisgau, Germany

  • Department of Ophthalmology University of Muenster Medical Center

    Münster, Germany

  • Department of Ophthalmology University of Udine

    Udine, Italy

  • Department of Ophthalmology, University Hospital, Nantes

    Nantes, France

  • Espaço Médico de Coimbra

    Coimbra, Portugal

  • Eye Clinic Sulzbach, Knappschaft Hospital Saar

    Sulzbach, Germany

  • Eye Unit, University Hospital Maggiore della Carità

    Novara, Italy

  • Institut Català de Retina (ICR), Clinical Trial Unit

    Barcelona, Spain

  • Institut de la Màcula Centro Médico Teknon

    Barcelona, Spain

  • Instituto de Oftalmologia Dr. Gama Pinto

    Lisbon, Portugal

  • Medical Retina Service, Operative Unit Ophthalmology / MultiMedica Spa (IRCCSMM)

    Milan, Italy

  • NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, NHS Foundation Trust

    London, United Kingdom

  • Royal Victoria Eye and Ear Research Foundation

    Dublin, Ireland

  • Swiss Visio Retina Research Center, Swiss Visio Montchoisi

    Lausanne, Switzerland

  • University Hospital Basel, University Eye Clinic, Basel

    Basel, Switzerland

  • Valles Ophthalmology Research, S.L.

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.